<DOC>
	<DOCNO>NCT02091986</DOCNO>
	<brief_summary>The purpose investigate Efficacy Safety Symbicort pMDI 80/2.25 μg Symbicort pMDI 80/4.5 μg , Compared Budesonide pMDI 80 μg , 2 Actuations Twice Daily , Children Ages 6 &lt; 12 Years Asthma 12 week .</brief_summary>
	<brief_title>A 12-Week Study Asthmatic Children Ages 6 &lt; 12 Years , Investigating Efficacy Safety Symbicort pMDI 80/2.25 μg Symbicort pMDI 80/4.5 μg , Compared With Budesonide pMDI 80 μg</brief_title>
	<detailed_description>A Phase 3 , 12-Week , Double-Blind , Randomized , Parallel-Group , Multicenter Study Investigating Efficacy Safety Symbicort pMDI 80/2.25 μg , 2 Actuations Twice Daily , Symbicort pMDI 80/4.5 μg , 2 Actuations Twice Daily , Compared Budesonide pMDI 80 μg , 2 Actuations Twice Daily , Children Ages 6 &lt; 12 Years Asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Has document clinical diagnosis asthma define ATS least 6 month prior Visit 2 Have morning prebronchodilator clinic FEV1 measure least 6 hour last dose inhale SABA least 48 hour last dose inhale LABA 60 % 100 % predict normal Demonstrated reversibility clinic FEV1 ≥12 % pre albuterol/salbutamol level within 15 30 minute administration standard dose albuterol/salbutamol . Have hospitalize least required emergency treatment asthmarelated condition 6 month prior Visit 1 Have require treatment systemic corticosteroid ( eg , oral , parenteral , rectal ) reason within 6 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>asthma , child , budesonide pMDI</keyword>
</DOC>